Available downloads

All links are direct pdf downloads of ECHO session presentations unless specified.

Important!

These files are provided for information only and are not intended to replace the clinical judgement of a practitioner. They should not be used alone to guide individual patient care.

« First ‹ Previous 1 2 3 4 5 Next › Last »
PDF Neurobiological pathways to addiction.
Session date: July 21, 2021
PDF Harm minimisation in primary care.
Session date: July 14, 2021
Summarises harm minimisation approaches and interventions in primary care.
PDF Social and developmental determinants of OUD in young people.
Session date: May 19, 2021
Opioid agonist therapy (OAT) and pregnancy.
Session date: May 5, 2021
*This presentation contains outdated information and has been removed. Lookout for an update soon*
PDF Opioids and cognitive impairment
Session date: April 28, 2021
PDF Opioids and hypogonadism.
Session date: April 21, 2021
Discusses the well established complication of opioid-induced hypogonadism
PDF Chronic pain and opioids
Session date: March 17, 2021
Session 9 of our foundation series
PDF High dose methadone to long-acting injectable buprenorphine transfers
Session date: March 10, 2021
Session 8 of our foundation series
PDF Stigma and OAT
Session date: February 24, 2021
Session 6 of our foundation series
PDF Poly-substance use and OAT
Session date: February 17, 2021
Session 5 of our foundation series
PDF OAT - issues in ongoing management.
Session date: February 10, 2021
Session 4 of our foundation series
PDF Overview of pharmacotherapies - methadone & buprenorphine including long-acting injectable buprenorphine.
Session date: February 3, 2021
Session 3 of our foundation series
PDF Opioid use disorder - assessment and treatment
Session date: January 27, 2021
Session 2 of our foundation series
PDF Introduction to opioid use disorder.
Session date: January 20, 2021
Session 1 of our foundation series
PDF Reducing risk of opioid-use-disorder
Session date: November 4, 2020
An overview of identifying and mitigating the risks of developing problematic opioid use.
« First ‹ Previous 1 2 3 4 5 Next › Last »